Science Corporation
Neurotech · Medical Devices · Biotech
Science Corp raises $400M Series D, valuing brain tech at $3.5B
November 17, 2026
Raised
$400M
The valuation reflects a retinal implant already restoring sight in Europe, with investors betting the next leg is US regulatory clearance.
- Science Corporation raised a $400 million Series D that values the brain-computer interface company at $3.5 billion, up from $1.5 billion in March, according to a person familiar with the deal cited by TechCrunch.
- Science was founded in 2021 by Max Hodak, former president of Neuralink, to build technology that connects directly to the human brain.
- Its first product, PRIMA, is a CE-marked wearable-and-implantable chip that restores limited reading vision to patients blinded by late-stage age-related macular degeneration, and it's already sold in Germany.
- The new capital will fund PRIMA's wider European rollout and a US bid through the FDA's Humanitarian Device Exemption pathway, a route reserved for rare conditions.
- Science is also designing first human trials of a biohybrid neural implant combining engineered neurons with silicon, working with Yale neurosurgeon Murat Günel to target Parkinson's disease and other brain disorders.
- The $3.5B valuation is roughly 2.3 times the $1.5B mark set by its $230 million Series C just eight months earlier, and lifts lifetime funding past $900M since 2021.
- Dealroom ranks the round above the 99th percentile of US health Series D deals over the past four years, amid a broader neurotech funding surge that includes Neuralink's $650M raise and Precision Neuroscience's $250M round.
- Pricing a neurotechnology startup at $3.5B on a CE-marked, commercially available device rather than a pre-clinical promise shows investors now rewarding regulatory and market traction over speculative brain-interface science.